Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBiome Tech Regulatory News (BIOM)

  • There is currently no data for BIOM

Interim Management Statement

6 Nov 2009 07:00

RNS Number : 0801C
Stanelco PLC
06 November 2009
 



6 November 2009

Stanelco plc ("the Company" or "the Group")

Interim Management Statement

Stanelco plc issues its interim management statement for the period from 1 January 2009 to 5 November 2009, as required by the UK Listing Authority's Disclosure and Transparency Rules.

Highlights

Sales to 30 September up 12% to ÂŁ13.4m

Trading performance in line with Board's expectations:

Continued growth in bioplastics division driven by interest in adopting sustainable products; increasing applications in new sectors

Radio frequency applications division sales order pipeline continued to strengthen; growing overseas sales in China and India

Closing cash position at 30 September ÂŁ3.7m, increased by working capital improvements

Board confident in full year outlook

Trading Update

Group revenues grew strongly during the nine months to 30 September 2009 and the Group's overall trading performance was in line with the Board's expectations.

Group revenues increased from £12.0m to £13.4m in the nine months to 30 September 2009, an increase of 12% compared with the same period last year. This reflected a 29% increase in bioplastic sales made directly by the Company, a 30% increase in sales in RF Applications division and an 8% increase in third party sales from our joint venture, Biotec.

Our cash position at 30 September 2009 was ÂŁ3.7m, strengthened since the half year by working capital improvements, including a reduction in stock levels following the summer production holiday.

Bioplastics division

In the Bioplastics division, the sales team that was established last year has had a number of successes in growing sales of the Group's existing biodegradable products into the market, delivering a 29% increase in the Company's bioplastic sales in the nine months to 30 September 2009. The division has broadened its customer base with over 40 new customers in 2009 and widened the set of end-use applications by a further 17 in the same period. The management remain encouraged by the division's opportunities for growth.

The product development team continues to work closely with a number of blue chip customers and mainstream plastics convertors to develop a widening range of biodegradable products that can substitute oil-based plastics. Whilst some of these development paths are still at an early stage, others are poised to deliver further growth in the coming months. The development team continues to focus on those accounts which we consider could have the maximum growth potential.

We continue to see strong demand for bioplastic products in the market, driven not only by concerns about waste disposal but also by the desire of many large corporations to switch to using sustainable resources in key brands. This switch to the use of "renewable" materials in advance of legislation is seen as both a branding enhancement and a hedge against further oil based price rises.   Sectors in which we are gaining traction include packaging, waste disposal, paper products, personal care, horticulture and electronics. The sales development work undertaken in the USA over the past year is now also gaining momentum. 

Our joint venture, Biotec, delivered 8% growth in its third party sales for the 9 months to 30 September 2009  compared with the same period last year.

Radio Frequency (RF) applications division 

In the RF Applications division, the team has been fulfilling a number of significant orders that have been won in the nine months to 30 September 2009, including the £0.3m order for RF furnaces disclosed in our interim results. Sales in the period increased by 30% compared with the same period last year including growth in both optical fibre furnaces and more general industrial equipment in which we are building a portfolio of customers making repeat orders.  The sales order pipeline continues to strengthen with a particular emphasis on sales in India and China. As a result, a new sales consultant has now been appointed for Stanelco dedicated to the Indian market, as this territory shows signs of increasing growth in the next few years.

Outlook

The Board continues to be confident in the outlook for the full year. Our focus continues to be on working closely with customers with the potential to deliver increases in revenue, whilst considering acquisition opportunities and other paths that could significantly increase the scale of the business and deliver shareholder value. 

- Ends -

For further information please contact:

Paul Mines, Chief Executive, Stanelco plc

Sue Bygrave, Group Finance Director, Stanelco plc

Tel: +44 (0) 2380 867100

Jonathon Brill/Caroline Stewart, 

Financial Dynamics

Tel: +44 (0) 20 7831 3113

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IMSBABRTMMJMBFL
Date   Source Headline
15th May 20067:01 amRNSAppointment of Adviser
3rd May 20061:05 pmRNSNotifiable Interest
2nd May 20064:58 pmRNSResult of AGM
2nd May 20062:00 pmRNSAGM Statement
10th Apr 20063:12 pmRNSAnnual Report and Accounts
7th Apr 20062:46 pmRNSAdditional Listing
13th Mar 20067:02 amRNSDirectorate Change
28th Feb 20067:02 amRNSPreliminary Results
24th Feb 20067:02 amRNSCooperation with Wal-Mart
14th Feb 20069:07 amRNSAdditional Listing
14th Feb 20067:00 amRNSUS FDA approval for Starpol
9th Feb 200610:42 amRNSIsraCaps new licence terms
9th Feb 20067:02 amRNSRe: BioProgress plc
16th Dec 20057:01 amRNSFunding for R&D facility
16th Dec 20057:01 amRNSPre Close Update
14th Dec 20057:01 amRNSLandmark deal with Perseco
8th Dec 200510:25 amRNSShare Listing Application
30th Nov 20055:40 pmRNSDirectorate Change
28th Nov 20059:24 amRNSBoard Changes
8th Nov 20057:01 amRNSPatent sale process update
3rd Nov 20054:47 pmRNSExercise of Options
1st Nov 20057:02 amRNSChange of Adviser
12th Oct 20057:00 amRNSApproval of Starpol
3rd Oct 20057:00 amRNSPatent Disposal & Update
22nd Sep 20057:02 amRNSRe Agreement
12th Sep 20057:03 amRNSDevelopment of capsule
5th Sep 20057:03 amRNSRe: Completion
30th Aug 20053:30 pmRNSDoc re. Result of EGM
30th Aug 200511:08 amRNSEGM Statement
30th Aug 20057:03 amRNSRe Agreement
5th Aug 200511:15 amRNSRe posting of circular
1st Aug 20057:01 amRNSDirector Appointment
28th Jul 20057:01 amRNSUpdate re: trials with ASDA
26th Jul 20057:00 amRNSContract Win
19th Jul 20057:00 amRNSRe Agreement
5th Jul 20057:01 amRNSRe Joint Venture
29th Jun 20057:00 amRNSInterim Results
22nd Jun 20057:00 amRNSUpdate re trials with Asda
8th Jun 20055:29 pmRNSAdditional Listing
8th Jun 200510:00 amRNSAppointment of Group MD
8th Jun 20057:50 amRNSPlacing of Ordinary Shares
6th Jun 20057:01 amRNSAcquisition
3rd Jun 20053:02 pmRNSIssue of Equity
23rd May 20057:01 amRNSRe Contract
17th May 200512:12 pmRNSAdditional Listing
10th May 20057:00 amRNSUpdate re. trials with Asda
29th Apr 20053:46 pmRNSHolding(s) in Company
25th Apr 20053:27 pmRNSDirector Shareholding
22nd Apr 20052:24 pmRNSResult of AGM
22nd Apr 200511:31 amRNSAGM Statement

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.